Jefferies Financial Group Begins Coverage on Vor Biopharma (NASDAQ:VOR)

Research analysts at Jefferies Financial Group started coverage on shares of Vor Biopharma (NASDAQ:VOR) in a report issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $50.00 price target on the stock. Jefferies Financial Group’s price objective points to a potential upside of 180.27% from the stock’s previous close.

Several other brokerages also recently weighed in on VOR. Wells Fargo & Company started coverage on shares of Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 price target for the company. JPMorgan Chase & Co. lowered their price objective on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. TD Cowen initiated coverage on Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating for the company. Finally, Citigroup started coverage on Vor Biopharma in a research note on Friday, January 9th. They issued a “buy” rating and a $50.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.67.

Vor Biopharma Stock Performance

Shares of Vor Biopharma stock opened at $17.84 on Monday. The stock has a market capitalization of $185.71 million, a PE ratio of -0.05 and a beta of 1.99. Vor Biopharma has a 52-week low of $2.62 and a 52-week high of $65.80. The company has a 50-day simple moving average of $14.19 and a two-hundred day simple moving average of $17.73.

Institutional Investors Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ariose Capital Management Ltd bought a new stake in Vor Biopharma in the 3rd quarter worth approximately $5,368,000. Fcpm Iii Services B.V. bought a new position in shares of Vor Biopharma during the 3rd quarter valued at $18,496,000. XTX Topco Ltd bought a new position in shares of Vor Biopharma during the 4th quarter valued at $229,000. Persistent Asset Partners Ltd purchased a new position in shares of Vor Biopharma in the 4th quarter worth $141,000. Finally, Susquehanna Portfolio Strategies LLC purchased a new position in shares of Vor Biopharma in the 4th quarter worth $134,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).